Dr. Mark Sherman graduated from the University of Chicago Pritzker School of Medicine in 1983 and completed a pathology residency at the New England Deaconess Hospital and a cytopathology fellowship at Montefiore Medical Center. His interests include the risk assessment, screening, biomarker development and validation, and prevention of gynecological and breast cancers. Dr. Sherman has broad experience in molecular epidemiology and clinical research, including lead participation in observational studies, clinical trials and investigations designed to secure FDA approvals for new devices. He has authored over 350 manuscripts and lectured throughout the U.S. and internationally on a range of topics and serves on multiple journal editorial boards, including the Journal of the National Cancer Institute.
Dr. Sherman serves on the Steering Committee of the American Association for Cancer Research Molecular Epidemiology Working Group, the Biospecimen Advisory Group of the American Cancer Society, the Avon Foundation for Women, and the Scientific Advisory Board for a multi-center DOD-funded award related to ovarian cancer led by researchers at Johns Hopkins. He has received NIH Merit Awards, the Exemplary Service Award from the NCI Division of Cancer Epidemiology and Genetics, NCI Technology Transfer and Performance Awards, and the United States and Canadian Academy of Pathology Service Award. He is a co-author of the Armed Forces Institute of Pathology fascicle on Tumors of the Cervix, Vagina and Vulva, and contributed to the revised World Health Organization monograph on the pathology and genetics of gynecologic tumors and breast cancer.
DCP Home |
Contact DCP |
Viewing Files |
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®